A review of current treatments strategies based on paromomycin for leishmaniasis

Published on Jun 1, 2020in Journal of Drug Delivery Science and Technology2.606
· DOI :10.1016/J.JDDST.2020.101664
A. P. S. Matos1
Estimated H-index: 1
(University of Toulouse),
A. L. Viçosa1
Estimated H-index: 1
(FIOCRUZ: Oswaldo Cruz Foundation)
+ 2 AuthorsCarla Holandino14
Estimated H-index: 14
(UFRJ: Federal University of Rio de Janeiro)
Abstract Leishmaniasis is a neglected disease caused by protozoan parasites of the Leishmania genus, which affects many people in several countries. This disease has three major clinical forms: cutaneous, mucocutaneous and visceral. The current treatments consist of an intravenous, intralesional or intramuscular administration of pentavalent antimonials, but other drugs can be used, among them, amphotericin B, pentamidine, paromomycin and miltefosine. However, these therapies have many side effects. Hence, there is an increase of studies searching for new formulations using different technologies and different routes of administration for leishmaniasis treatment. Paromomycin sulfate (PM) is an aminoglycoside antibiotic, belonging to class III of biopharmaceutical classification system, used intravenously and topically with leishmanicidal activity. This review will provide a general overview of PM current leishmaniasis treatments and new PM formulations. Treatments using PM are available in ointments or creams for topical administration and PM solution for intramuscular administration. The topical treatment with PM presents low efficacy, probably related to low drug permeability across the skin. To improve PM permeability and efficacy, researchers are establishing micro and nanotechnologies. However, further studies are still required to investigate more physicochemical properties and in vitro/in vivo parameters.
  • References (115)
  • Citations (0)
📖 Papers frequently viewed together
25 Citations
33 Citations
38 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Naomi E. Aronson (USU: Uniformed Services University of the Health Sciences)H-Index: 26
#2Christie A. JoyaH-Index: 1
1 CitationsSource
#1Vijay MishraH-Index: 14
#2Kuldeep K. BansalH-Index: 5
Last. Jessica M. RosenholmH-Index: 32
view all 7 authors...
Solid lipid nanoparticles (SLNs) are nanocarriers developed as substitute colloidal drug delivery systems parallel to liposomes, lipid emulsions, polymeric nanoparticles, and so forth. Owing to their unique size dependent properties and ability to incorporate drugs, SLNs present an opportunity to build up new therapeutic prototypes for drug delivery and targeting. SLNs hold great potential for attaining the goal of targeted and controlled drug delivery, which currently draws the interest of rese...
9 CitationsSource
#1Juana Schwartz (University of Navarra)H-Index: 5
#2Esther MorenoH-Index: 10
Last. Socorro Espuelas (University of Navarra)H-Index: 22
view all 10 authors...
Abstract Background Cutaneous leishmaniasis (CL) skin lesions are the result of a deregulated immune response, which is unable to eliminate Leishmania parasites. The control of both, parasites and host immune response, is critical to prevent tissue destruction. The skin ulceration has been correlated with high TNF-α level. Objective Because human anti-TNF-α antibodies (Ab) have been successfully assayed in several mice inflammatory diseases, we hypothesized that their anti-inflammatory effect co...
#1Swati Kapil (Punjabi University)H-Index: 1
#2Pankaj Kumar Singh (Punjabi University)H-Index: 6
Last. Om Silakari (Punjabi University)H-Index: 18
view all 3 authors...
Abstract Leishmaniasis is an infectious disease caused by various species of protozoan parasite known as Leishmania, which is transmitted to its mammalian host via bite of an infected sandfly. Clinically, Leishmaniasis appears as following four conditions: Cutaneous Leishmaniasis, Mucocutaneous Leishmaniasis, Visceral Leishmaniasis/Kala-azar, Post Kala azar dermal Leishmaniasis. Current therapies include pentavalent antimonials, Amphotericin B, Paromomycin, Miltefosine, Pentamidine, Sitamaquine....
9 CitationsSource
#1Aline Fernanda de Souza (USP: University of São Paulo)H-Index: 6
#2Débora Soares Souza Marins (USP: University of São Paulo)H-Index: 2
Last. Nádia Araci Bou-Chacra (USP: University of São Paulo)H-Index: 8
view all 8 authors...
Abstract Leishmaniases are infectious diseases caused by an intracellular protozoan in humans by 20 different species of Leishmania among more than 53 species. There are at least twelve million cases of infections worldwide and three hundred and fifty million people are at risk in at least 98 developing countries in Africa, South-East Asia, and the Americas. Only Brazil presented high burden for both visceral leishmaniasis (VL) and cutaneous (CL). Chemotherapy is the main means of dealing with t...
7 CitationsSource
#1Mostafa Mahinroosta (IUST: Iran University of Science and Technology)H-Index: 7
#2Zohreh Jomeh Farsangi (Tehran University of Medical Sciences)H-Index: 2
Last. Zahra Shakoori (Tehran University of Medical Sciences)H-Index: 4
view all 4 authors...
Abstract Hydrogels are a unique class of three dimensional cross-linked polymeric networks that can hold a large fraction of aqueous solvents and biological fluids within their structures. Nowadays, hydrogels have attracted a growing interest of many scientists in different fields of research. Intelligent hydrogels have found a significant role in a wide variety of applications such as drug delivery systems, tissue engineering, optics, diagnostics and imaging. The purpose of this paper is to pre...
28 CitationsSource
Abstract Lesihmaniasis is one of the major neglected tropical disease caused by the parasite of the genus Leishmania. The disease has more than one clinical forms and the visceral form is considered fatal. With the lack of potential vaccine, chemotherapy is the major treatment source considered for the control of the disease in the infected people. Drugs including amphotericin B and miltefosine are widely used for the treatment, however, development of resistance by the parasite towards the admi...
14 CitationsSource
#1Eduardo Ricci-Júnior (UFRJ: Federal University of Rio de Janeiro)H-Index: 11
#2Luciana Betzler de Oliveira de Siqueira (UFRJ: Federal University of Rio de Janeiro)H-Index: 3
Last. Ralph Santos-OliveiraH-Index: 10
view all 7 authors...
Abstract The use of nanosystems as diagnosing and therapy systems is increasing each year. There are several nanosystems available and the most prominent ones are: mesoporous silica, nanoemulsion and polymeric nanoparticles. With characteristics like low toxicology, and easy-producing process they have advantages when compared with the traditional system used, as they show specific targeting, controlled release, and higher penetration. In this study we tested three different nanocarriers (polyme...
3 CitationsSource
#1Jaiberth Antonio Cardona-Arias (UdeA: University of Antioquia)H-Index: 8
#2Liliana López-Carvajal (UdeA: University of Antioquia)H-Index: 3
Last. Iván Darío Vélez (UdeA: University of Antioquia)H-Index: 34
view all 4 authors...
Background Cutaneous leishmaniasis causes a high disease burden in Colombia, and available treatments present systemic toxicity, low patient compliance, contraindications, and high costs. The purpose of this study was to estimate the cost-effectiveness of thermotherapy versus Glucantime in patients with cutaneous leishmaniasis in Colombia.
1 CitationsSource
#1Susana C. P. S. de Oliveira (UFBA: Federal University of Bahia)H-Index: 5
#2Evaristo João da Ordem Trahamane (UFBA: Federal University of Bahia)H-Index: 1
Last. Alb. Pinheiro (UFBA: Federal University of Bahia)H-Index: 35
view all 8 authors...
Improvement of Higher Education Personnel—CAPES (Post-Doctoral research grant - SCPSO) and the National Council for Scientific and Technological Development—CNPq (MSci Grant - EJOT).
6 CitationsSource
Cited By0